Abstract
Objectives. We evaluated the validity of a short hydration regimen of high dose cislatin (≥60 mg/m2/cycle)-based chemotherapy in patients with lung cancer or malignant pleural mesothelioma. Methods. We retrospectively compared the nephrotoxicity of a short hydration regimen with the nephrotoxicity of an usual hydration regimen, and examined the transition rate from hospitalization treatment to outpatient treatment in a short hydration regimen. Results. All subjects received cisplatin (≥60 mg/m2)-based chemotherapy. Nephrotoxicity of a short hydration regimen was equally tolerable and safe as an usual hydration regimen. Transition rate from hospitalization treatment to outpatient treatment was 87%.Conclusion. The results of this study indicate that a short hydration regimen could be feasible for outpatient treatment.
